Clinical amyloid imaging in Alzheimer's disease
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Background The hypothesis that amyloid deposition is the leading cause of Alzheimer's disease (AD) is supported by findings in transgenic animal models and forms the basis of clinical trials of anti-amyloid agents. According to this theory, amyloid deposition causes severe damage to neurons many years before onset of dementia via a cascade of several downstream effects. This hypothesis has, however, not yet been directly tested in human beings because of the very limited possibility of diagnosing amyloid deposition in vivo, which until recently required either brain biopsy or PET imaging with an on-site cyclotron and radiochemistry laboratory. Moreover, a clinical diagnosis of AD requires that patients have dementia, at which stage any effective treatment aimed at reducing amyloid deposition will probably be too late. Recent developments The amyloid imaging tracers flutemetamol, florbetapir, and florbetaben labelled with (18)F have been developed for PET; they can be produced commercially at central cyclotron sites and subsequently delivered to clinical PET scanning facilities. These tracers are currently undergoing formal clinical trials to establish whether they can be used to accurately image fibrillary amyloid and to distinguish patients with AD from normal controls and those with other diseases that cause dementia. They might also be used as biomarkers to predict development of AD before onset of dementia and to assess the effect of anti-amyloid therapy. Negative amyloid…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
The citation lists are queued
They are fetched later and appear here then.
References 49 · Cited by 240
Metadata
- Authors
- Herholz, K., & Ebmeier, K.
- Affiliations
- University of Manchester (GB)
- Warneford Hospital (GB)
- Corresponding author
- Herholz, Karl
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 10
- Issue
- 7
- Pages
- 667-670
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2122860201
- Cited by
- 240
- References
- 49
- Citations by year
- 2025: 7 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 17 · 2020: 8 · 2019: 13 · 2018: 31 · 2017: 21 · 2016: 14 · 2015: 21 · 2014: 26 · 2013: 31 · 2012: 20
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid imaging, amyloid PET tracers, florbetapir, florbetaben, anti-amyloid therapy, amyloid biomarkers, preclinical Alzheimer's disease, dementia diagnosis, amyloid hypothesis
- MeSH terms
- Aged, Alzheimer Disease, Brain, Humans, Radionuclide Imaging, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical amyloid imaging in Alzheimer's disease. https://app.cochat.ai/papers/10.1016/s1474-4422(11)70123-5
- The paper
- Herholz, K., & Ebmeier, K. (2011). Clinical amyloid imaging in Alzheimer's disease. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(11)70123-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.